how the treatment landscape of dlbcl is changing: r-chop vs pola-r-chp
Published 1 year ago • 2.3K plays • Length 5:30Download video MP4
Download video MP3
Similar videos
-
3:12
polarix: polatuzumab vedotin and r-chp superior to r-chop in dlbcl
-
6:12
coalition: glofitamab r-chop or glofitamab pola-r-chp in patients with high-risk dlbcl
-
1:02
the changing standard of care in dlbcl
-
3:01
how the treatment of dlbcl and fl are changing in the uk
-
4:00
current treatment landscape of dlbcl
-
2:34
evolving treatment landscape of dlbcl
-
3:48
coalition: glofitamab r-chop or glofitamab pola-r-chp in high-risk dlbcl
-
2:44
polarix study: frontline therapy in dlbcl
-
3:25
linda, transformed lymphoma survivor | stories of hope
-
10:09
understanding diffuse large b-cell lymphoma with jennifer amengual, md
-
29:38
dlbcl treatment approaches: what you need to know
-
1:45
improving the frontline treatment of dlbcl
-
6:33
new data on dlbcl in the uk and its impact on treatment decisions
-
1:28
how the standard of care for dlbcl is changing with the introduction of novel agents
-
1:12
smart stop: moving away from r-chop in dlbcl
-
1:31
the current state of treatment for limited-stage dlbcl
-
2:03
novel treatment approaches for early-stage dlbcl
-
4:01
first- and second-line treatment in dlbcl
-
1:25
the changing treatment landscape of hl: de-escalating treatment intensity while maintaining efficacy
-
0:42
targeted therapies for dlbcl treatment
-
1:38
using pet to predict failure to salvage therapy in patients with dlbcl
-
1:33
zamtocabtagene autoleucel for the treatment of patients with r/r dlbcl